A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

One cheerleader is rewriting what determination looks like by pushing boundaries on the mat while managing a chronic sleep ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

Narcolepsy is estimated to affect one in 2,000 people in the United States and some 3 million worldwide, according to the Narcolepsy Network, a non-profit patient advocacy group.